Anti-MAG Neuropathy: Development of a Therapeutic Glycopolymer: MIP: Polyneuron Pharmaceuticals AG - Texts

Home
Main Navigation
Content
Search
Help

Font Standard Bold
Login

Research unit

INNOSUISSE

Project number

17485.1 PFLS-LS

Project title

Anti-MAG Neuropathy: Development of a Therapeutic Glycopolymer: MIP: Polyneuron Pharmaceuticals AG

Texts for this project

	German	French	Italian	English
Short description		-	-
Abstract		-	-

Inserted texts

Category	Text
Short description (German)	Anti-MAG Neuropathy: Development of a Therapeutic Glycopolymer
Short description (English)	Anti-MAG Neuropathy: Development of a Therapeutic Glycopolymer: MIP: Polyneuron Pharmaceuticals AG
Abstract (German)	The aim of this project is to define preclinical lead candidates for the treatment of anti-myelin-associated\|glycoprotein (MAG) neuropathy, a disabling IgM autoantibody-mediated autoimmune disorder of the\|peripheral nervous system. Currently, there is no effective treatment and agents to block/deplete the\|pathogenic autoantibodies are of substancial clinical interest. Several lead candidates (glycopolymers) will\|be synthesized and evaluated in an animal model of the disease.
Abstract (English)	The aim of this project is to define preclinical lead candidates for the treatment of anti-myelin-associated\|glycoprotein (MAG) neuropathy, a disabling IgM autoantibody-mediated autoimmune disorder of the\|peripheral nervous system. Currently, there is no effective treatment and agents to block/deplete the\|pathogenic autoantibodies are of substancial clinical interest. Several lead candidates (glycopolymers) will\|be synthesized and evaluated in an animal model of the disease.